Skip to main content

Table 1 Immunosuppressed patients with COVID-19 completing treatment without relapse of the viral infection

From: Novel treatment combining antiviral and neutralizing antibody-based therapies with monitoring of spike-specific antibody and viral load for immunocompromised patients with persistent COVID-19 infection

Factors

Patient identification

1

2

3

4

5

6

7

8

9

10

Age (years)

51

74

49

94

51

66

72

57

51

84

Sex (male/female)

M

M

F

F

F

F

M

M

M

M

Primary disease

Follicular lymphoma

Follicular lymphoma

Myasthenia gravis

Myasthenia gravis

Rheumatoid arthritis

Kidney transplant

Kidney transplant

Kidney transplant

Liver transplant

Chronic myeloid leukemia

Chronic lymphocytic leukemia

Other comorbidity

None

Hypertension

Thyrotoxicosis

Hypertension

Epilepsy

Hypertension

Hypertension

Diabetes mellitus

Hypertension

Diabetes mellitus

Nephrotic syndrome

None

Diabetes mellitus

Coronary heart disease

COVID-19 vaccination

Yes

Yes

No

Yes

No

Yes

Yes

Yes

No

Yes

Anti-CD20 antibody

Obinutuzumab

Rituximab

Obinutuzumab

None

None

None

None

None

None

None

None

Immunosuppressive agents for primary disease

Cyclophosphamide

Prednisolone

Cyclophosphamide

Prednisolone

Tacrolimus

Tacrolimus

Prednisolone

Tacrolimus

Mycophenolate mofetil

Everolimus

Prednisolone

Tacrolimus

Mycophenolate mofetil

Methylprednisolone

Tacrolimus

Mycophenolate mofetil

Methylprednisolone

Tacrolimus

Mycophenolate mofetil

Everolimus

Iguratimod

Tocilizumab

Prednisolone

Prednisolone

Initial antiviral therapy

Switched antiviral therapy

Remdesivir

Remdesivir

Nirmatrelvir/Ritonavir

Remdesivir

Nirmatrelvir/Ritonavir

Remdesivir

Molnupiravir

Remdesivir

Remdesivir

Nirmatrelvir/Ritonavir

Remdesivir

Remdesivir

Nirmatrelvir/Ritonavir

Remdesivir

Remdesivir

Neutralizing antibody-based therapy

Sotrovimab

Casirivimab/Imdevimab

Sotrovimab

Casirivimab/Imdevimab

Casirivimab/Imdevimab

Sotrovimab

Sotrovimab

Sotrovimab

Sotrovimab

Casirivimab/Imdevimab

Sotrovimab

Initial Ct value

18.6

19.8

25.3

18.2

19.6

25

17.9

22.4

15

25.6

Initial spike-specific antibody

Negative

Negative

163 U/mL

Negative

Negative

Negative

Negative

Negative

Negative

1.41 U/mL

Length of antiviral and antibody-based therapy

10 days

14 days

9 days

10 days

10 days

21 days

20 days

18 days

8 days

7 days

Length of hospital stay

14 days

19 days

13 days

28 days

13 days

23 days

43 days

18 days

12 days

17 days